Figure 9.

The survival analysis of identified SCMs in MM patients in Cohort 2. (A), 1-Methylhistidine; (B), Asymmetric dimethylarginine; (C), 5′-Methylthioadenosine; (D), Butyrylcarnitine; (E), N-Acetylputrescine; (F), Creatinine; (G), DL-Glutamate; (H), 3-Dehydroxycarnitine. Twenty-six Subjects of RG group and 29 subjects of AG groups in Cohort 2 was conduted to survival analyses. The cutoff value was calculated by ROC analysis and Youden index. Those 55 subjects were grouped into lower patients group and higher patients group based on the cutoff value. Patients with metabolite value less than cutoff value was incorporated into lower patient goup and those patients with metabolite value more than cutoff vuale was incorporated into higher paitent group, respectively. There was none of unit for the cutoff values of metabolites shown in Figure on account of the standard substance of metabolites identified in HILIC column is absent and we could not obtain the concentration of each of metabolites shown in Figure. The metabolites shown in Figure in each of samples was quantitative by the peak area generated from mass spectrometer.